L

Lung Center of the Philippines | Pulmonary, Critical Care and Sleep Medicine Department

Research site
(Unclaimed)
Location
Quezon Avenue, Quezon City, National Capital Region, Philippines
Site insights

Top conditions

COVID-19 (6 trials)

Tuberculosis (4 trials)

Non-Small-Cell Lung Carcinoma (3 trials)

Human Influenza (2 trials)

Multidrug-Resistant Tuberculosis (2 trials)

Top treatments

Linezolid
TBAJ876
Talactoferrin
C21
GT0918
Trimodulin
Ritonavir
Delamanid
Deupirfenidone
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

5 of 19
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting in...

Active, not recruiting
SARS-CoV-2 Infection
Drug: S-217622
Drug: Placebo

This multicenter, two-stage, open-label, randomized trial will aim to assess the efficacy, safety, optimal duration, and pharmacokinetics (PK) of Del...

Enrolling
Pulmonary Tuberculosis
Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
Drug: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)

The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to plac...

Enrolling
Community-acquired Pneumonia
Drug: Trimodulin
Drug: Placebo (human albumin 1%)

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults wit...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: Deupirfenidone

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial...

Enrolling
Multidrug-Resistant Tuberculosis
Drug: Background Regimen (BR)
Drug: Bedaquiline (TMC207)

Trial sponsors

A

Agennix (1 trial)

Boehringer Ingelheim logo

Boehringer Ingelheim (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems